Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Nov 10 - Nov 15
Asian Pac J Cancer Prev (2011) 12(11):31136
No published research characterizes adverse events at sustained injectable doses above 5-10 mg/week in humans
c2024 Nov 13 [cited 18 Feb 2025]
Retatrutide acts as a triple incretin receptor agonist, simultaneously activating three distinct receptors: GLP-1 receptors stimulating insulin secretion in a glucose-dependent manner, slowing gastric emptying, and reducing appetite GIP receptors enhancing insulin release and potentially improving fat metabolism Glucagon receptors increasing energy expenditure and promoting fat breakdown in the liver This multi-receptor activity produces pronounced effects on body weight, blood glucose, lipid metabolism, and hepatic fat
US$ 23.39
US$ 20.67
US$ 24.74
